Wechselwirkungen · RoActemra
RoActemra 162 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 80
HOS-120388 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone, dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect. Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1102–1734 im Abschnitt